1. Home
  2. DH vs ENGN Comparison

DH vs ENGN Comparison

Compare DH & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Definitive Healthcare Corp.

DH

Definitive Healthcare Corp.

HOLD

Current Price

$0.99

Market Cap

107.6M

Sector

Technology

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$1.46

Market Cap

647.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
DH
ENGN
Founded
2011
1999
Country
United States
Canada
Employees
N/A
82
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
107.6M
647.1M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
DH
ENGN
Price
$0.99
$1.46
Analyst Decision
Hold
Buy
Analyst Count
5
6
Target Price
$3.08
$21.08
AVG Volume (30 Days)
243.0K
2.1M
Earning Date
05-07-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
63.28
N/A
EPS
N/A
N/A
Revenue
$241,521,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.74
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.89
$1.49
52 Week High
$4.70
$12.25

Technical Indicators

Market Signals
Indicator
DH
ENGN
Relative Strength Index (RSI) 45.69 22.46
Support Level $0.93 N/A
Resistance Level $1.10 $8.32
Average True Range (ATR) 0.08 0.56
MACD 0.01 -0.71
Stochastic Oscillator 38.20 0.07

Price Performance

Historical Comparison
DH
ENGN

About DH Definitive Healthcare Corp.

Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.

About ENGN enGene Holdings Inc.

enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Share on Social Networks: